Pharmafile Logo
Pharmafocus logo
Advanced Search

ulcerative colitis

Showing 15 posts of 35 posts found.

Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults

January 21, 2020
Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis

NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …

News
takeda_deerfield_hq

Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

September 27, 2019
Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis

September 5, 2019
Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis

Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …

News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019
Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …

News
janssen_latest_logo_on_sign_closer

Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials

March 13, 2019
Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis

Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …

News

Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis

October 22, 2018
Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab

Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara shows promise across two dosages in ulcerative colitis

October 9, 2018
Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis

Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …

News
merckincweb2

MSD’s ulcerative colitis drug scores expanded indication in Europe

July 9, 2018
Sales and Marketing Europe, MSD, pharma, ulcerative colitis

New Jersey-based multinational MSD have announced that the European Commission (EC) has approved Simponi (golimumab) for early dose optimisation in …

News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio secures Japanese approval in ulcerative colitis

July 2, 2018
Sales and Marketing Entyvio, Japan, Takeda, pharma, ulcerative colitis

Takeda Pharmaceutical has announced that its monoclonal antibody, Entyvio (vedolizumab), has been approved for the treatment of patients with moderately …

News

Pfizer’s Xeljanz becomes first JAK inhibitor approved in US for active ulcerative colitis

May 31, 2018
Sales and Marketing FDA, Pfizer, US, Xeljanz, pharma, ulcerative colitis

Pfizer has revealed that its Janus kinase (JAK) inhibitor Xeljanz (tofacitinib) has received FDA approval for the treatment of adult …

News
gilead-sciences

Gilead terminates Phase II/III study for ulcerative colitis antibody

September 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, ulcerative colitis

Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative …

News

Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial

July 29, 2016
Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis

Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …

News
humira_abbott_

New Humira data shows improved quality of life in ulcerative colitis patients

June 23, 2016
Research and Development AbbVie, Humira, data, ulcerative colitis

New data on Humira (adalimumab) has been presented at the British Society of Gastroenterology, demonstrating the drug’s efficacy and improvement …

News
takeda_research_centre

Takeda presents long-term Entyvio data in CD and UC

March 21, 2016
Manufacturing and Production, Research and Development Crohn's, Crohn's and Colitis, Entyvio, Takeda, ulcerative colitis

Japan’s Takeda has presented interim findings from the GEMINI Long-Term Safety (LTS) study of ulcerative colitis drug Entyvio (vedolizumab) at …

News
pfizer-building-logo1web

Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials

March 21, 2016
Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025